Cognition Therapeutics, Inc. (CGTX)
Automate Your Wheel Strategy on CGTX
With Tiblio's Option Bot, you can configure your own wheel strategy including CGTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CGTX
- Rev/Share 0.0
- Book/Share 0.1985
- PB 1.2527
- Debt/Equity 0.0386
- CurrentRatio 2.0882
- ROIC -4.209
- MktCap 15411471.0
- FreeCF/Share -0.5032
- PFCF -0.4954
- PE -0.4616
- Debt/Assets 0.0202
- DivYield 0
- ROE -1.9442
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CGTX | B. Riley Securities | Neutral | Buy | $1 | $1.5 | Dec. 19, 2024 |
News
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision and Ophthalmology (ARVO) showing the potential for zervimesine (CT1812) to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD).
Read More
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
- End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Read More
Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Cognition Therapeutics, Inc (NASDAQ:CGTX ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Mayank Mamtani - B. Riley Securities Daniil Gataulin - Chardan Operator Greetings, and welcome to the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call.
Read More
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call PURCHASE, N.Y.
Read More
About Cognition Therapeutics, Inc. (CGTX)
- IPO Date 2021-10-08
- Website https://www.cogrx.com
- Industry Biotechnology
- CEO Ms. Lisa Ricciardi
- Employees 25